The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

Moderna is counting on revenue from newer mRNA vaccines, including a next generation Covid shot, to make up for falling sales ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions ...

The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, ...

Several of the committee members asked at Thursday’s meeting about the FDA’s new vaccine approval framework ... 2 – the ...

The FDA will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

The US FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for use in adults aged 65 and older.